Bristol-Myers says Celgene take over ‘best path’ for investors

U.S. drugmaker Bristol-Myers Squibb urged shareholders on Wednesday to support its planned takeover of Celgene Corp, as it faces opposition to the $74 billion deal from at least two prominent investors.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News